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PXPEDITED REVIEW
one Marrow Transplantation Shows Superior
theroprotective Effects of Gene Therapy With
polipoprotein A-I Milano Compared With Wild-
ype Apolipoprotein A-I in Hyperlipidemic Mice
ai Wang, MD, Behrooz G. Sharifi, PHD, Theresa Pan, MS, Lei Song, MD, Ada Yukht, MS,
rediman K. Shah, MD, FACC
os Angeles, California
OBJECTIVES We tested the hypothesis that gene therapy using apolipoprotein A-I Milano (apoA-IMilano)
is more effective than that using wild-type apolipoprotein A-I (apoA-I) in reducing
atherosclerosis.
BACKGROUND Apolipoprotein A-I Milano is a naturally occurring mutant with established antiatherogenic
activity; however, its relative antiatherogenic efficacy compared with that of wild-type apoA-I
remains unclear.
METHODS We performed bone marrow transplantation in female double-knockout mice lacking both
the apoE and apoA-I genes using male donor mice–derived bone marrow that had been
transduced with a retroviral vector alone or retroviral vector expressing wild-type apoA-I or
apoA-IMilano gene under the control of macrophage-specific scavenger receptor A promoter.
Mice were fed a high-cholesterol diet and killed 24 weeks after transplantation, at which time
the extent of aortic atherosclerosis was determined.
RESULTS Compared with vector control (n 12), apoA-IMilano gene therapy (n 15) reduced aortic
atherosclerosis by 65% (p  0.001) and plaque macrophage immunoreactivity by 58% (p 
0.0001), whereas wild-type apoA-I (n  11) reduced atherosclerosis by 25% (p  0.1) and
plaque macrophage immunoreactivity by 23% (p  0.05). The apoA-IMilano gene therapy
was significantly more effective in reducing atherosclerosis (p  0.05) and macrophage
immunoreactivity (p  0.001) compared with wild-type apoA-I. The circulating levels of
cholesterol, lipoprotein profile, and apoA-IMilano or wild-type apoA-I were comparable
among the groups. Apolipoprotein A-I Milano was more effective than wild-type apoA-I in
promoting macrophage cholesterol efflux.
CONCLUSIONS Macrophage-specific expression of the apoA-IMilano gene is more effective than wild-type
apoA-I in reducing atherosclerosis and plaque inflammation despite comparable circulating
levels of the transgene and lipid profile. (J Am Coll Cardiol 2006;48:1459–68) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.040the American College of Cardiology Foundation
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Iubstantial efforts have been made to promote cholesterol
fflux to prevent or treat atherosclerosis. For example,
iver-specific overexpression of the apolipoprotein A-I
apoA-I) transgene was found to increase high-density
ipoprotein (HDL) cholesterol and apoA-I levels, reducing
therosclerosis in C57BL/6 mice (1) and hyperlipidemic
ice (2,3). A significant reduction in atherosclerosis was
ound after somatic gene transfer of human apoA-I into
ow-density lipoprotein (LDL) receptor knockout mice fed
high-fat diet (4,5). Conversely, mice lacking the apoA-I
ene had significantly increased atherosclerosis (6). Collec-
From the Atherosclerosis Research Center and the Division of Cardiology, Burns
nd Allen Research Institute and Department of Medicine, Cedars Sinai Medical
enter and David Geffen School of Medicine at UCLA, Los Angeles, California.
his work was supported by grants from the National Institutes of Health (ROI
L50566), The Eisner Foundation, the Entertainment Industry Foundation, the
ilken Family Foundation, United Hostesses, and The Heart Foundation. Dr.
harifi is an established investigator of the American Heart Association. Dr. Shah is
scientific advisor to Pfizer, Inc.r
Manuscript received January 27, 2006; revised manuscript received June 19, 2006,
ccepted July 10, 2006.ively, these data show that apoA-I has antiatherogenic
ctivity in animal models.
Apolipoprotein A-I Milano (apoA-IMilano) is a natu-
ally occurring mutant of apolipoprotein A-I characterized
y Arg173¡ Cys173 substitution (7). The human carriers of
his mutation have very low levels of HDL cholesterol and
igh levels of triglycerides and yet do not show increased
ardiovascular risk (8). We and others have previously
hown that intravenous recombinant apoA-IMilano inhibits
rogression and induces rapid regression and remodeling of
therosclerosis in hypercholesterolemic rabbits and mice
hile attenuating endothelial dysfunction (9–13). Based on
hese promising preclinical results, a small phase II human
rial of patients with acute coronary syndromes was con-
ucted in which once-weekly injections of recombinant
poA-IMilano were shown to induce rapid coronary ather-
ma regression within 5 weeks (14). Although these results
uggest that intravenous infusions of recombinant apoA-
Milano could be used to rapidly induce atherosclerosis
egression/remodeling, the need for repeated intravenous
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ApoA-I Gene Therapy October 3, 2006:1459–68njections and the logistical issues associated with large-scale
roduction of recombinant apoA-IMilano could pose a
ignificant challenge to the widespread use of this novel
pproach. An attractive or complementary approach could
e the use of gene transfer to exploit the atheroprotective
ffect of apoA-IMilano. In addition, the relative atheropro-
ective effects of apoA-IMilano compared with those of
ild-type apoA-I are unknown.
In this study, we used transplantation of retrovirally
ransduced bone marrow cells to provide proof of the
oncept that apoA-IMilano gene transfer is effective in
arkedly reducing atherosclerosis in a murine model. Fur-
hermore, we also compared the atheroprotective effects of
poA-IMilano and wild-type apoA-I gene transfer.
ETHODS
nimals. The apoA-I/apoE double-knockout mice were
indly provided by Dr. Linda Curtiss (Department of Immu-
ology, The Scripps Research Institute, La Jolla, California)
nd housed in microisolator cages.Mice were healthy through-
ut these studies and showed no differences in feeding pattern
r body weight. Animal care and experimental procedures were
erformed with the approval of and according to the regula-
ions of the Cedars-Sinai Medical Center Institutional Animal
are and Usage Committee.
Sample size calculations showed that the number of mice
eeded per group was 7 based on a statistical ability to detect
30% relative difference in percent of aorta covered by
laque with 90% power and p 0.05 assuming that controls
ill have 10% of aortic surface covered by plaque. There-
ore, we have used 8 to 10 mice per group.
onstruction of retroviral vector. To generate double-
nockout mice with the ability to express human apoA-I
nd apoA-IMilano, bone marrow was harvested from male
ice, marrow cells were transduced with retrovirus express-
ng apoA-I or apoA-IMilano, and then female mice were
econstituted with the transduced bone marrow cells. To
arget the expression of transgenes to macrophages, we used
acrophage-specific promoter, essentially as described pre-
iously (15). We received the retroviral construct containing
he 868-bp cDNA of human apoA-I gene under the control
f scavenger receptor A (SR-A) promoter from Dr. Sergio
Abbreviations and Acronyms
apoA-I  apolipoprotein A-I
apoA-IMilano  apolipoprotein A-I Milano
DPPC  dipalmitoyl phosphatidylcholine
ELISA  enzyme-linked immunosorbent assay
GFP  green fluorescent protein
HDL  high-density lipoprotein
LDL  low-density lipoprotein
PCR  polymerase chain reaction
RT  reverse transcriptase
SR-A  scavenger receptor Aazio (Vanderbilt University). The PT67 viral packaging well line was used to package the plasmid and generate
etrovirus-expressing wild-type human apoA-I (15).
We used the SR-A–apoA-I plasmid to generate SR-A–
poA-IMilano by site-directed mutagenesis, using a Strat-
gene (La Jolla, California) kit essentially as described by the
anufacturer. The DNA sequencing confirmed missense mu-
ation of the apoA-I gene (173 arg:cys). Because promoter and
oncoding sequences of the 2 constructs are identical, this
llowed us to express comparable levels of apoA-I and apoA-
Milano in vivo and in vitro. This is further confirmed by
nzyme-linked immunosorbent assay (ELISA).
estern blot analysis for human apoA-I and apoA-
Milano. To investigate the expression of apo A-I and
poA-IMilano by retroviral vector, the conditioned media
rom PT67 cells were collected, concentrated by Amicon
icrocon-100 columns (Millipore, Waltham, Massachu-
etts), and analyzed by 10% sodium dodecyl sulfate-
olyacrylamide gel electrophoresis. This is followed by
ransferring the separated proteins to a nitrocellulose mem-
rane and then incubating the membrane with a polyclonal
abbit antihuman apoA-I (Calbiochem, San Diego, Cali-
ornia) antibody and a horseradish peroxidase conjugated
ntirabbit immunoglobulin G (Sigma, St. Louis, Missouri)
ntibody. The visualization of the bound antibody was
erformed by chemiluminescence using an ECL kit (Am-
rsham Pharmacia Biotech, Piscataway, New Jersey).
one marrow transplantation. Bone marrow transduction
as performed essentially as described previously (15).
riefly, bone marrow was taken from the femurs and tibias
f 6- to 8-week-old apoA-I/apoE double-knockout male
ice, 3 days after tail vein injection of 150 mg/kg of
-fluorouracil (American Pharmaceutical Partners, Los An-
eles, California). The bone marrow was resuspended at 1
o 2  106 nucleated cells/ml in RPMI 1640 supplemented
ith 15% fetal bovine serum, 2 mmol/l L-glutamine,
enicillin-streptomycin, 50 ng/ml mouse stem cell factor, 10
g/ml mouse interleukin-6, and 10 ng/ml interleukin-3 (all
rom R&D Systems, Minneapolis, Minnesota). After 48 h,
one marrow cells were diluted 1:1 with RPMI and Dul-
eco’s Modified Eagle Medium supplemented with 15%
etal bovine serum, cytokines, and 4 g/ml polybrene. The
iluted cells were co-cultured with irradiated (40 Gy) viral
roducer cells expressing apoA-I or apoA-IMilano for 48 h.
mpty vector was used as a control. On the day of
ransplantation, the bone marrow cells were gently flushed
nd collected, washed, and counted. The cells were resus-
ended in RPMI supplemented with 5 U/ml heparin and 1
106 cells were injected into each female recipient mouse
hat had been lethally irradiated (1,000 Gy). At 4 weeks
fter transplantation, mice were placed on a high-fat diet for
0 weeks and then killed. Blood was collected 1 day before
eing fed a high-fat diet and then at intervals, 4 weeks, 8
eeks, 12 weeks, and 20 weeks afterward.
one marrow engraftment assessment using Y-chro-
osome polymerase chain reaction (PCR). The DNA
as isolated from the bone marrow of recipient mice using a
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October 3, 2006:1459–68 ApoA-I Gene TherapyNIQ-10 universal DNA-purifying kit (Gentaur Molecular
roducts, Brussels, Belgium). Oligonucleotide primers for the
yr locus were as follows: forward, 5=-CTG CTG TGA ACA
AC ACT AC-3=; reverse 5=-GAC TCC TCT GAC TTC
CT TG-3=. Amplification of beta-actin served as an internal
ontrol. All PCR amplifications also included DNA from a
ale C57BL/6 mouse (positive control) and DNA from a
emale C57BL/6 mouse (negative control). Amplification
ycles consisted of an initial denaturation step of 96°C for 4
in; followed by 35 cycles of denaturation at 94°C for 60 s,
nnealing at 62°C for 60 s, and extension at 72°C for 2 min;
nd a final 72°C extension for 7 min. These primers amplified
DNA fragment of 395 bp. The PCR products were analyzed
y agarose electrophoresis using a 1.5% gel.
poA-I expression. The reverse transcriptase (RT)-PCR
as performed on the total RNA isolated from liver of
ecipient mice reconstituted with apoA-I or apoA-IMilano
xpressing retroviruses. The PCR was performed with
he following primer sequences for apoA-I: 5=-
AGGACCTGGCCACTGTGTA-3= sense and 5=-
CTCCTCCTGCCACTTCTTC-3= antisense (301 bp).
rimers for beta-actin were as follows: forward, 5=-GAG
CC TTC AAC ACC CCA GCC-3=; reverse, 5=-AAT
TC ACG CAC GAT TTC CC-3= (401 bp). The cycling
onditions were an initial denaturation for 10 min at 94°C
ollowed by 35 cycles of 94°C for 1 min, 60°C for 1 min, and
2°C for 1 min.
ipoprotein analysis. Fasting blood samples were collected
rom bone marrow transplant recipient mice by retro-orbital
enous plexus puncture using heparinized tubes under isoflu-
ane anesthesia (Medeva Pharmaceuticals, Rochester, New
ork). Total cholesterol was measured using a Cholesterol
eagent Enzymatic Kit (Thermo Electron, Louisville, Colo-
ado). Lipoprotein profile was assessed by fast protein liquid
hromatography.
LISA for the detection of human apoA-I and apoA-
Milano. Serum levels of human apoA-I or apoA-IMilano
n the bone marrow transplant recipients were determined
y ELISA (15). Briefly, ELISA plates were coated with an
ntihuman apoA-I monoclonal antibody (Calbiochem) at a
oncentration of 1 g/ml and incubated at 4°C overnight.
he wells were washed, blocked with fetal bovine serum,
nd diluted standards (Calbiochem) or serum samples were
dded to the wells and incubated at 4°C overnight. After
ashing, rabbit antihuman apoA-I antibody was added and
ncubated at room temperature for 1 h. After washing, a
eroxidase-conjugated goat-antirabbit antibody (Calbio-
hem) was added and the color was developed by addition of
,2=-azino-bis-3-ethylbenz-thiazoline-6-sulfonic acid
Sigma). Absorbance was measured at 405 nm on a micro-
late reader (Molecular Devices, Sunnyvale, California).
erum human apoA-I and apoA-IMilano levels were cal-
ulated by comparison with the standard curve.
ssessment of atherosclerosis. All image acquisitions and
easurements were made by an observer blinded to treat-
ent assignment. The extent of the atherosclerotic lesions Rn the aorta and innominate artery were quantified after oil
ed O staining, as described previously (10,11). Briefly, the
horacic cavity was opened; the aortic arch as well as the
orta were exposed, and were photographed under a dis-
ecting microscope. After capturing the images, most of the
ascular tree was dissected intact. The luminal surface was
xposed, and then the aortic tissue was fixed with Histo-
hoice tissue fixative (Amresco, Solon, Ohio). After tissue
xation, the adventitial tissue was removed and aortic tissue
as stained with oil red O. The aortas were pinned to a dark
urface, and images were captured by using a Spot digital
amera (Diagnostic Instruments, Sterling Heights, Michi-
an). The extent of the atherosclerotic lesions was quanti-
ed using Image-Pro Plus (version 4, Media Cybernetics,
ilver Spring, Maryland). Lesions were reported as percent-
ge of the total aortic area consisting of thoracic aorta
ending at the final intercostal artery), and abdominal aorta
nding at the iliac bifurcation.
For innominate artery sections, aortic arch was fixed in 4%
araformaldehyde overnight and then embedded in Optimal
utting Temperature (OCT). The frozen tissues were serially
ectioned into 8-m sections from the aortic arch using a Leica
ryostat and kept in a70°C freezer for1 month before use.
he lesion areas were quantified by Image-Pro Plus using the
ematoxylin-stained sections (mean of 8 sections per mouse; 5
ice per group). Aortic sinus plaque area was determined by
easuring the cross-sectional lesion area from serial sections of
ortic sinus that were stained with oil red O and measured by
anual tracing of the lesion, which was identified by a
ombination of lipid staining and histologic morphology.
mmunostaining. Macrophage immunoreactivity was de-
ected by immunostaining of frozen sections (8 m) with a
:100 dilution of rat antimouse murine monocyte/
acrophage (MOMA-2) monoclonal antibody (Accurate
hemical and Scientific, Westbury, Connecticut). The
xpression of apoA-I or apoA-IMilano proteins in the
econstituted mice was determined by immunostaining of
rozen sections with a 1:25 dilution of rabbit antihuman
poA-I antibody (Calbiochem) essentially as described pre-
iously (10,11). After washing, the sections were incubated
ith the appropriate secondary antibodies, followed by color
evelopment. The sections were counterstained with hema-
oxylin. Photomicroscopy was performed using an Olympus
icroscope. The percentage of plaque area occupied by
OMA-2 staining, reflecting macrophage immunoreactiv-
ty, was calculated from the captured images using the
mage-Pro Plus software.
aser microdissection. For laser microdissection, 7-m-
hick OCT aortic root sections were used. The macro-
hage-rich areas were defined by MOMA-2 staining (5
ice per group). The macrophage-rich areas of serial
ections were dissected (PixCell LCM System Arcturus,
unnyvale, California), and the fragments were captured
nd used for total RNA extraction using a Strataperp Total
NA Microprep Kit (Stratagene).
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ApoA-I Gene Therapy October 3, 2006:1459–68holesterol efflux. Cholesterol efflux was measured in
acrophages expressing wild-type apoA-I or apoA-
Milano genes as wells as in macrophages treated with
xogenous apoA-I or apoA-IMilano proteins. To measure
holesterol efflux by macrophages that produce apoA-I or
poA-IMilano, RAW cells (American Type Culture) were
ransduced with retroviral vector expressing apoA-I or
poA-IMilano, essentially as described above. The ELISA
nalysis of culture medium from transduced cells revealed
hat the cells transduced with wild-type apoA-I produced
71 ng/ml of protein and cells transduced with apoA-
Milano produced 167 ng/ml of protein. Control cells were
ransduced with vector-expressing green fluorescent protein
GFP). The transduced cells were plated in 6-well plates (1
105 cells per well). After 24 h, media were removed and
eplaced with loading media containing 1 ci/well of
H-cholesterol (Amersham, Piscataway, New Jersey) and 70
g/ml of oxidized LDL. Cells were loaded for 48 h, after
hich the monolayers were washed and equilibrated for 18
o 20 h in DMEM/1% bovine serum albumin (BSA). After
ashing, cells were exposed to DMEM/1% BSA efflux media
or 4 h and then 100 l was used for scintillation counting.
To further compare the effects of apoA-I and apoA-
Milano proteins on cholesterol efflux, we also used perito-
eal macrophages isolated from the double-knockout mice
s well as untransduced RAW cells. Cells were loaded with
H-cholesterol as described above. The cholesterol loaded
ells were then incubated with efflux media (DMEM  1%
SA) supplemented with 200 g/ml of either apoA-I or
poA-IMilano proteins that were complexed with phospho-
ipid, dipalmitoyl phosphatidylcholine (DPPC) at the pro-
ein to phospholipid ratio of 1:2.7 for 4 h. Cholesterol efflux
as measured as previously described.
tatistical evaluation. Statistical analyses were performed
y analysis of variance followed by the Bonferroni Multiple
omparison test. Each post-hoc comparison was done at
he significance level of 0.01 with 3 groups each at p 0.05.
he Prism 4.0 software (GraphPad, San Diego, California)
as used for all calculations. All data are represented as
ean  SD. Values with p  0.05 were considered
tatistically significant.
ESULTS
xpression of the transgenes in the packaging cell line. To
stablish that the retroviral construct expresses the gene,
edium collected from the PT67 packaging cell line was
sed for Western blot analysis (data not shown). We
ound that the construct expresses both the monomeric
28 kDa) and dimeric (56 kDa) forms of apoA-IMilano.
he level of the dimer is approximately 30% higher than
hat of the monomer. The construct expressing wild-type
poA-I only expressed the monomeric form of apoA-I
ransduced bone marrow cells. The empty vector was
sed for control. These data indicate that the retroviruses
re capable of expressing the transgenes in vitro.
t
mngraftment of the transplanted bone marrow. The en-
raftment of the transplanted bone marrow cells was deter-
ined by examining the expression of the Y chromosome
provided by the male donors of the bone marrow) in the
ecipient female mice. The DNA was extracted from the
one marrow of female recipient mice, and the Y chromo-
ome engraftment was determined by PCR (data not
hown). We found that the livers from 3 randomly selected
ice injected with apoA-IMilano, apoA-I, and control
ector expressed the Y chromosome. The female and male
hromosomes were used as negative and positive controls.
hese data show that the transplanted bone marrow cells
ere engrafted.
xpression of the transgene in liver and circulating
onocytes of recipient mice. To determine whether the
ngraftment is associated with transgene expression, the
xpression of the transgene was determined by RT-PCR
sing total RNA isolated from the livers of the recipient
ice (data not shown). The liver was chosen because
pproximately 70% of the transplanted bone marrow cells
re known to be retained in the liver (16). We found that a
01-bp PCR product corresponding with the wild-type and
ilano variants of apoA-I were detected in the randomly
elected mice transplanted with apoA-IMilano or wild-type
poA-I transduced bone marrow cells. The 3 mice trans-
lanted with bone marrow cells transduced with the control
mpty vector did not express the transgene. These data
howed that the engrafted bone marrow cells expressed the
ransgenes.
We used the SR-A promoter, a monocyte/macrophage-
pecific promoter, to express the transgene. To determine
hether the circulating monocytes express the transgenes,
lood was collected from the recipient mice and the expression
f transgenes was determined by RT-PCR in isolated mono-
ytes (data not shown). We found that monocytes of mice
eceiving bone marrow cells transduced with the retrovirus
igure 1. Expression of apolipoprotein A-I (apoA-I) or apolipoprotein
-I Milano (apoA-IM) in the serum of recipient double-knockout mice.
erum levels of wild-type apoA-I or apoA-IM at 4, 8, 12, and 24 weeks
fter bone marrow transplantation are shown. Serum from a group of mice
ransplanted with the empty vector is used as a control. The data represent
ean  SD from 5 mice per group.
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October 3, 2006:1459–68 ApoA-I Gene Therapyxpressing apoA-I or apoA-IMilano expressed the genes,
hereas the monocytes from the recipients of bone marrow
ells transduced with the empty vector did not express the
ransgene. These data indicate that the circulating monocytes
rom the recipient mice express the transgene.
xpression of transgenes in circulating blood. To com-
are the expression levels of the transgenes in vivo, we
xamined the serum level of apoA-I and apoA-IMilano in the
ecipient mice using an ELISA (Fig. 1). As expected, apoA-I
as not detected in the serum before transplantation. The
poA-I was detected as early as 4 weeks post-transplantation
103 69 ng/ml, n 5), at 8 weeks post-transplantation (i.e.,
weeks on high-fat diet) the level was 93 58 ng/dl (n 5),
t 12 weeks post-transplantation (8 weeks on high-fat diet) the
evel was 124  34 ng/dl (n  5), and at 24 weeks post-
ransplantation (20 weeks on high-fat diet) the level was 113
3 ng/dl (n 5). These levels of serum apoA-I were similar to
hose of apoA-IMilano. At 4 weeks post-transplantation the
evel was 96 66 ng/ml, at 8 weeks 95 55 ng/dl, at 12 weeks
24 44 ng/dl, and at 24 weeks 115 35 ng/dl. Collectively,
hese data show there was no statistically significant difference
etween the serum levels of apoA-I and apoA-IMilano.
irculating lipoprotein profile. The total circulating cho-
esterol levels at 24 weeks were comparable in the 3 groups,
veraging 1,123  53 mg/dl in vector control groups, 1,127
269 mg/dl in the wild-type apoA-I group, and 1,173 
37 mg/dl in apoA-IMilano group. Most of the cholesterol
as found to be associated with the very-low-density
ipoprotein fraction, followed by the intermediate-density
ipoprotein/LDL fractions (Fig. 2). No difference in the
istribution of cholesterol was found among the 3 groups of
ice. Both the apoA-IMilano and wild-type apoA-I were
rimarily found to be associated with the HDL fractions.
igure 2. Comparative serum lipoprotein profile of mice on a high-fat die
he recipient mice transplanted with wild-type apolipoprotein A-I (A), apolipo
hromatography.ocalization of apoA-I and apoA-IMilano in the athero-
clerotic plaque. Anti–apoA-I antibody was used to deter-
ine whether the transgenes were expressed in the lesions.
he atherosclerotic lesions of mice receiving empty vector
onsisted mainly of lipid core and foam cells, and no apoA-I
r apoA-IMilano was detected (Fig. 3A). In contrast, mice
xpressing apoA-I (Fig. 3B) or apoA-IMilano (Fig. 3C)
howed strong immunoreactivity for the corresponding
roteins, mostly at the base of the lesions and around and
ithin the lipid cores. The wild-type and mutant forms of
poA-I found in the plaque may have originated from
irculating proteins, because we have detected the proteins
n serum. In addition, because the circulating monocytes
xpressed the genes for wild-type and mutant forms of the
rotein, it is conceivable that at least some of the proteins
ay have originated from the local monocyte-derived mac-
ophages found in the plaque.
ffect on aortic atherosclerosis. The mean lesion area in
ice expressing wild-type apoA-I was 12.0  1.7 (n  11),
ersus 16.4  2.6 (n  12) in mice receiving the empty
ector, reflecting a 25% reduction (p  0.1) (Fig. 4). In
ontrast, the mean lesion area in the mice expressing
poA-IMilano was 5.6  0.6 (n  15), reflecting a 65%
eduction compared with empty vector control (p  0.001)
nd 52% reduction compared with mice expressing wild-
ype apoA-I (p  0.05).
ffect on innominate artery and aortic sinus atherosclerosis.
he mean innominate artery lesion area (mm2) in mice
xpressing wild-type apoA-I was 0.138  0.007, versus
.197 0.022 in mice receiving the empty vector, reflecting
29% reduction (p 0.01) (Fig. 5A). In contrast, the mean
esion area in mice expressing apoA-IMilano was 0.098 
.010, reflecting a 50% reduction compared with empty
and 20 weeks. Distribution of cholesterol was determined in serum fromt for 8
protein A-I Milano (M) or vector control (C) using standard superose-6
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ApoA-I Gene Therapy October 3, 2006:1459–68ector control (p  0.001) and a 29% reduction compared
ith mice expressing wild-type apoA-I (p  0.05). Simi-
arly, the mice transplanted with bone marrow expressing
poA-IMilano had significantly less aortic sinus plaque
ompared with mice transplanted with wild-type apoA-I
xpressing bone marrow (Fig. 5B).
The reduction in lesion size was associated with reduced
acrophage immunoreactivity (Fig. 6). The immunoreac-
ivity was reduced by 23% in mice expressing wild-type
poA-I as compared with vector control mice (15.3  0.8%
s. 11.7  0.9%, p  0.05). Similarly, a 58% reduction in
he macrophage immunoreactivity was observed in mice
xpressing apoA-IMilano compared with vector control
ice (15.3  0.8% vs. 6.5  0.9%, p  0.001). Thus, the
acrophage immunoreactive area was 44% less in mice
xpressing apoA-IMilano compared with those expressing
ild-type apoA-I (6.5 0.9% vs. 11.7 0.9%, p 0.001).
ocal expression of transgene. Figure 7A shows represen-
ative sections before and after laser dissection. The
acrophage-rich dissected segments from 5 mice were
ooled and RT-PCR was performed using primers specific
or apoA-I. As shown in Figure 7B, the groups of mice that
igure 3. Representative aortic sinus lesions showing apolipoprotein A-I
amples reconstituted with cells expressing apoA-I (B) or apoA-IMilano (C
ll 5 mice per group examined.
igure 4. Average percent lesion area (mean  SD) in en fasse aortas after
il red O staining in vector control group (VC; n  12), wild-type
polipoprotein A-I (apoA-I) gene recipients (A-I; n  11), and apoli-
oprotein A-I Milano (apoA-IMilano) gene recipients (A-IM; n 15) are
hown.
a
aeceived bone marrow transduced with a retrovirus express-
ng either apoA-I or apoA-IM show a 301-bp PCR
ragment corresponding to apoA-I. In contrast, the control
roup containing recipient double-knockout mice that were
ransplanted with bone marrow cells transduced with a
A-I) or apolipoprotein A-I Milano (apoA-IMilano) expression in mice
mpared with no expression in vector controls (A). Data were consistent in
igure 5. Average percent lesion area (mean  SD) in innominate artery
A) and aortic sinus (B) in vector control group (VC; n  5) , wild-type
polipoprotein A-I (apoA-I) gene recipients (A-I; n  5), and apolipopro-
ein A-I Milano (apoA-IMilano) gene recipients (A-IM; n  5) are
hown. Mice expressing apoA-IMilano had significantly smaller lesion(apo
) coreas compared with vector control mice and recipients of wild-type
poA-I.
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October 3, 2006:1459–68 ApoA-I Gene Therapyontrol vector did not show a PCR-amplified fragment. All
issected tissues were positive for the expression of 410-bp
CR product corresponding to the beta-actin gene.
holesterol efflux. One of the important mechanisms for
he atheroprotective effects of apoA-I and apoA-IMilano is
heir ability to promote cholesterol efflux from macrophages
n arterial lesions. It has been previously reported that
acrophage expression of apoA-I reduced atherosclerosis
y increasing cholesterol efflux (17). Therefore, we evalu-
ted the relative effect of apoA-I and apoA-IMilano on
acrophage cholesterol efflux. At 4 h, we observed a
ignificant increase in the cholesterol efflux by RAW cells
xpressing apoA-IMilano (p 0.001) or apoA-I (p 0.01)
ompared with control cells expressing GFP (Fig. 8). The
holesterol efflux was significantly higher in cells expressing
poA-IMilano compared with cells expressing wild-type
poA-I (p  0.001). This was further substantiated when
ntransduced RAW cells or peritoneal macrophages derived
rom apoA-I/apoE double-knockout mice were exposed to
quivalent quantities of wild-type apoA-I or apoA-IMilano
omplexed with phospholipid DPPC (Fig. 8). Similar to the
ransduced cells, exogenous apoA-IMilano was found to be
ignificantly more effective than wild-type apoA-I in pro-
igure 6. Representative macrophage immunoreactivity in the innominate
D). The macrophage immunoreactive area was significantly lower in recipi
r recipients of wild-type apolipoprotein A-I (A-I).oting macrophage cholesterol efflux (p  0.001). aISCUSSION
revious studies have shown that macrophage-specific ex-
ression of apoA-I through bone marrow transplantation
educes atherosclerosis in apoE null mice (15,18). We have
reviously shown that apoA-IMilano prevented progression
f aortic atherosclerosis and reduced the lipid and macro-
hage content of plaques in apoE knockout mice (10),
ossibly through tissue cholesterol mobilization (11). These
bservations were recently supported by a small clinical trial
n which weekly infusion of recombinant apoA-IMilano
as shown to induce rapid coronary atheroma regression
ithin 5 weeks (14). However, the relative antiatherogenic
ffects of wild-type apoA-I and apoA-IMilano remain
nclear. To compare the relative atheroprotective effects of
ild-type apoA-I and apoA-IMilano, we used apoA-I/
poE double-knockout mice for two major reasons. First,
he absence of endogenous apoA-I prevents confounding
hat could have occurred as a result of interaction between
xogenous human apoA-I and endogenous mouse protein
e.g., generation of high-molecular-weight forms of
poA-I) (19). Second, the double-knockout mice allowed us
o use a single anti–apoA-I antibody to detect expression
evels of the 2 human proteins in vitro and in vivo, thus
lesions of mice are shown (A to C) and are presented as quantitative data
f apolipoprotein A-I Milano (A-IM) compared with vector controls (VC)arteryvoiding the variability that could have arisen if we would
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ApoA-I Gene Therapy October 3, 2006:1459–68igure 7. (A) Representative frozen sections of aortic sinus plaques before and after laser microdissection. The serial sections from control, apolipoprotein A-I (apoA-I),
nd apoA-IM recipient mice were selected (5 mice per group) and the macrophage-rich areas were dissected. (B) Total RNA was extracted from the dissected segments
rom recipient mice transplanted with bone marrow transduced empty vector (VC), wild-type apoA-I (A-I), or apolipoprotein A-I Milano (A-IM) genes.
everse-transcriptase polymerase chain reaction (RT-PCR) was performed using primers specific for beta-actin (lanes 1 to 3, 410 bp) or apoA-I (lanes 6 to 8, 301 bp).
ane 4 is a positive control (PC) for apoA-I derived from packaging cell lines; lane 5 is negative control (NC) from PCR in the absence of primers.
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ffinities.
Using this animal model, we found that reconstitution of
he double-knockout mice with bone marrow cells express-
ng apoA-IMilano is significantly more effective than
poA-I in reducing both aortic and innominate artery
therosclerosis. We observed a 65% reduction in aortic
therosclerosis in mice expressing apoA-IMilano compared
ith the vector control group, which is substantially greater
han the 25% reduction observed with wild-type apoA-I.
he magnitude of reduction in atherosclerosis with wild-
ype apoA-I observed in our study is comparable with the
0% lesion reduction by apoA-I reported previously (18).
onsistent with the results in the en fasse aorta, we also
ound a greater reduction in innominate artery and aortic
inus lesions with apoA-IMilano compared with wild-type
poA-I. In addition, we observed that the reduction of
therosclerotic lesions was associated with a 58% decrease in
acrophage immunoreactivity in mice expressing apoA-
Milano compared with a 23% decrease observed with
ild-type apoA-I, reflecting a further 44% reduction in the
acrophage immunoreactivity in the mice expressing apoA-
Milano compared with mice expressing wild-type apoA-I.
otably, the antiatherogenic activity of apoA-IMilano and
igure 8. Cholesterol efflux from cholesterol-loaded macrophages. Tra
polipoprotein A-I (A-I), or apolipoprotein A-I Milano (A-IM) were us
ddition, nontransduced RAW cells were loaded with 3H-cholesterol, an
ipalmitoyl phosphatidylcholine (DPPC) alone or DPPC with 200 g/m
erformed with the peritoneal macrophages that were isolated from apoA-
riplicate determination. The experiments were repeated twice with similapoA-I was observed despite low levels of systemic apoA-I ar apoA-IMilano (approximately 100 ng/dl) and without
ny changes in the circulating lipoprotein profile, consistent
ith previous reports (15,18). However, laser microdissec-
ion RT-PCR studies have shown that the transgenes
RNA are expressed in macrophage-rich areas of the
laque, suggesting that local expression of transgenes could
n part contribute to the observed effects of apoA-I and
poA-IMilano. Collectively, these data support and extend
ur earlier observations, in which intravenous injection of
poA-IMilano into apoE knockout mice was found to
apidly mobilize tissue cholesterol and reduce plaque lipid
nd macrophage content of aortic lesions (11).
Previous studies have shown that the antiatherogenic
ctivity of macrophage-specific apoA-I expression is likely
ediated by increased cholesterol efflux and decreased foam
ell formation (17,18). Our in vivo data support these
ndings and show that apoA-IMilano is significantly more
ffective than apoA-I in reducing lipid-rich atherosclerotic
esions. Our in vitro cholesterol efflux data provide one
otential explanation for the differential atheroprotective
ffects of apoA-IMilano and wild-type apoA-I. Our results
how that expression of apoA-I or apoA-IMilano by mac-
ophages promotes cholesterol efflux; however, apoA-
Milano was found to be significantly more effective than
ed RAW cells expressing genes for green fluorescent protein (GFP),
cholesterol efflux in the absence of exogenous extracellular acceptors. In
en cholesterol efflux was measured 4 h after loading in the presence of
ither apoA-I (A-I) or apoA-IMilano (A-IM). A similar experiment was
/apoE/ double-knockout mice. Each bar shows the mean  SD of a
lts.nsduc
ed for
d th
l of epoA-I in stimulating cholesterol efflux. This increased
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ApoA-I Gene Therapy October 3, 2006:1459–68holesterol efflux-promoting activity of apoA-IMilano ver-
us wild-type apoA-I was also observed in untransduced
acrophage cell lines and peritoneal macrophages exposed
o exogenous protein phospholipid complexes. These data
re consistent with previous reports comparing the choles-
erol efflux promoting activity of apoA-IMilano and
poA-I. Franceschini et al. (20) compared the capacity of
erum from carriers of apoA-IMilano mutation and from
ontrol subjects to extract cholesterol from Fu5AH cells.
hey reported that serum from carriers of apoA-IMilano
as more efficient than serum from normal subjects in
romoting cholesterol efflux. This increased efficiency of
poA-IMilano may be related to the protease-sensitive
exible C-terminal domain of apoA-IMilano that is not
hared by wild-type apoA-I (21). In addition to this lipid
obilization activity, apoA-IMilano has been found to be
ore effective than wild-type apoA-I in preventing LDL
xidation (22), providing further evidence in favor of the
uperior atheroprotective activity of apoA-IMilano com-
ared with wild-type apoA-I.
tudy limitations. Although these results were obtained in
ontrolled experimental conditions associated with severe dys-
ipidemia, it is not possible to predict precisely whether these
elative differences in efficacy would be maintained in human
isease, in which less severe dyslipidemia is more common.
imilarly, whether gene therapy using intravenous or intramus-
ular injection of the vectors rather than bone marrow trans-
lantation would show similar differences remains unclear, and
ur laboratory is continuing work in that direction.
ummary. We provide experimental proof of the idea that
espite comparable and low levels of circulating transgene
xpression, gene therapy using macrophage-specific expres-
ion of apoA-IMilano is significantly more effective than
hat using wild-type apoA-I in reducing atherosclerosis and
laque inflammation in hyperlipidemic apo A-I/apoE dou-
le knockout mice, possibly because of its increased
holesterol-efflux-promoting effect.
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